Have a feature idea you'd love to see implemented?
Let us know!
PCSA Processa Pharmaceuticals Inc
Price (delayed)
$1.3
Market cap
$4.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.4
Enterprise value
-$1.22M
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a
Highlights
The EPS has soared by 81% YoY and by 15% from the previous quarter
PCSA's debt is down by 38% year-on-year and by 15% since the previous quarter
PCSA's net income has soared by 60% YoY but it is down by 4% QoQ
Processa Pharmaceuticals's quick ratio has shrunk by 66% YoY and by 59% QoQ
Processa Pharmaceuticals's equity has decreased by 34% YoY and by 32% QoQ
Key stats
What are the main financial stats of PCSA
Market
Valuations
Earnings
Shares outstanding
3.26M
Market cap
$4.23M
Enterprise value
-$1.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$10.22M
EBITDA
-$10.14M
Free cash flow
-$9.28M
Per share
Balance sheet
Liquidity
EPS
-$5.4
Free cash flow per share
-$3.11
Book value per share
$2.11
Revenue per share
$0
TBVPS
$2.55
Total assets
$7.6M
Total liabilities
$1.58M
Debt
$118,829
Equity
$6.02M
Working capital
$5.93M
Debt to equity
0.02
Current ratio
4.82
Quick ratio
3.59
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-130.2%
Return on equity
-151.1%
Return on invested capital
-2,248.1%
Return on capital employed
-169%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCSA stock price
How has the Processa Pharmaceuticals stock price performed over time
Intraday
-3.7%
1 week
-1.52%
1 month
-2.84%
1 year
-80.3%
YTD
-80.57%
QTD
-5.11%
Financial performance
How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.37M
Net income
-$10.22M
Gross margin
N/A
Net margin
N/A
Processa Pharmaceuticals's operating income has surged by 60% YoY but it has decreased by 4% QoQ
PCSA's net income has soared by 60% YoY but it is down by 4% QoQ
Growth
What is Processa Pharmaceuticals's growth rate over time
Valuation
What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 81% YoY and by 15% from the previous quarter
PCSA's P/B is 85% below its 5-year quarterly average of 4.0 and 44% below its last 4 quarters average of 1.1
Processa Pharmaceuticals's equity has decreased by 34% YoY and by 32% QoQ
Efficiency
How efficient is Processa Pharmaceuticals business performance
The ROA has grown by 37% YoY but it has contracted by 12% from the previous quarter
Processa Pharmaceuticals's return on equity has increased by 35% YoY but it has decreased by 16% QoQ
Processa Pharmaceuticals's return on invested capital has increased by 34% YoY but it has decreased by 15% QoQ
Dividends
What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCSA.
Financial health
How did Processa Pharmaceuticals financials performed over time
PCSA's total liabilities has surged by 69% year-on-year and by 49% since the previous quarter
Processa Pharmaceuticals's quick ratio has shrunk by 66% YoY and by 59% QoQ
PCSA's debt is 98% smaller than its equity
PCSA's debt is down by 38% year-on-year and by 15% since the previous quarter
Processa Pharmaceuticals's equity has decreased by 34% YoY and by 32% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.